Beta Bionics (NASDAQ:BBNX) CFO Stephen Feider Sells 15,018 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 15,018 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $20.76, for a total transaction of $311,773.68. Following the sale, the chief financial officer directly owned 44,041 shares of the company’s stock, valued at approximately $914,291.16. The trade was a 25.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Stephen Feider also recently made the following trade(s):

• On Friday, September 5th, Stephen Feider sold 100 shares of Beta Bionics stock. The shares were sold at an average price of $21.00, for a total transaction of $2,100.00.
• On Tuesday, September 2nd, Stephen Feider sold 1,462 shares of Beta Bionics stock. The shares were sold at an average price of $18.86, for a total transaction of $27,573.32.
• On Friday, August 22nd, Stephen Feider sold 4,413 shares of Beta Bionics stock. The shares were sold at an average price of $17.01, for a total transaction of $75,065.13.
• On Tuesday, August 19th, Stephen Feider sold 5,587 shares of Beta Bionics stock. The shares were sold at an average price of $17.03, for a total transaction of $95,146.61.

Beta Bionics Price Performance

Shares of BBNX stock opened at $22.26 on Friday. Beta Bionics, Inc. has a 1 year low of $8.89 and a 1 year high of $26.66. The firm has a fifty day moving average price of $19.21 and a 200-day moving average price of $15.78.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.12. The business had revenue of $23.24 million for the quarter, compared to the consensus estimate of $19.73 million. Beta Bionics has set its FY 2025 guidance at EPS.

Analyst Ratings Changes

BBNX has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Beta Bionics in a report on Saturday, September 27th. Lake Street Capital initiated coverage on shares of Beta Bionics in a report on Thursday, June 12th. They issued a “buy” rating and a $30.00 target price for the company. The Goldman Sachs Group set a $26.00 target price on shares of Beta Bionics and gave the stock a “buy” rating in a report on Wednesday. Robert W. Baird set a $17.00 target price on shares of Beta Bionics and gave the stock a “neutral” rating in a report on Wednesday, July 30th. Finally, Truist Financial upped their target price on shares of Beta Bionics from $21.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.44.

Institutional Trading of Beta Bionics

Several hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company lifted its stake in Beta Bionics by 10.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,558 shares of the company’s stock worth $343,000 after purchasing an additional 2,205 shares in the last quarter. Strs Ohio purchased a new stake in Beta Bionics in the 1st quarter worth $29,000. Legal & General Group Plc lifted its stake in Beta Bionics by 197.4% in the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after purchasing an additional 2,639 shares in the last quarter. CWM LLC purchased a new stake in shares of Beta Bionics during the 2nd quarter valued at about $58,000. Finally, Values First Advisors Inc. raised its position in shares of Beta Bionics by 13.2% during the 2nd quarter. Values First Advisors Inc. now owns 42,563 shares of the company’s stock valued at $620,000 after buying an additional 4,978 shares in the last quarter.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.